521,327 Shares in Immunocore Holdings PLC Sponsored ADR $IMCR Acquired by Braidwell LP

Braidwell LP acquired a new stake in shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 521,327 shares of the company’s stock, valued at approximately $16,552,000. Braidwell LP owned 1.02% of Immunocore at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Millennium Management LLC increased its holdings in shares of Immunocore by 334.3% in the 3rd quarter. Millennium Management LLC now owns 1,265,965 shares of the company’s stock worth $45,993,000 after acquiring an additional 974,463 shares during the period. Vestal Point Capital LP bought a new position in Immunocore in the 4th quarter worth about $20,305,000. Janus Henderson Group PLC bought a new position in Immunocore in the 4th quarter worth about $15,734,000. Bellevue Group AG increased its stake in shares of Immunocore by 14.5% in the third quarter. Bellevue Group AG now owns 2,796,803 shares of the company’s stock valued at $101,608,000 after purchasing an additional 354,973 shares during the period. Finally, Tang Capital Management LLC increased its stake in shares of Immunocore by 14.0% in the fourth quarter. Tang Capital Management LLC now owns 2,628,538 shares of the company’s stock valued at $91,237,000 after purchasing an additional 322,930 shares during the period. Institutional investors and hedge funds own 84.50% of the company’s stock.

Immunocore Stock Up 1.4%

NASDAQ IMCR opened at $37.37 on Thursday. Immunocore Holdings PLC Sponsored ADR has a 12 month low of $27.56 and a 12 month high of $40.71. The company has a market capitalization of $1.92 billion, a P/E ratio of -101.00 and a beta of 0.74. The company’s 50 day simple moving average is $34.25 and its 200 day simple moving average is $31.68. The company has a debt-to-equity ratio of 0.94, a current ratio of 4.47 and a quick ratio of 4.44.

Immunocore (NASDAQ:IMCR) last issued its earnings results on Friday, August 7th. The company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). Immunocore had a negative return on equity of 4.54% and a negative net margin of 4.20%. Equities research analysts expect that Immunocore Holdings PLC Sponsored ADR will post 0.06 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

IMCR has been the subject of several analyst reports. Zacks Research upgraded Immunocore from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, August 5th. JPMorgan Chase & Co. started coverage on Immunocore in a research report on Friday, August 21st. They issued an “overweight” rating and a $50.00 target price on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunocore in a research note on Friday, July 17th. Wall Street Zen cut Immunocore from a “buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Finally, Morgan Stanley set a $43.00 price target on Immunocore in a report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $56.38.

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.